Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

ClinicalTrials.gov ID: NCT00947856

Public ClinicalTrials.gov record NCT00947856. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 15, 2026, 4:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study

Study identification

NCT ID
NCT00947856
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Seagen Inc.
Industry
Enrollment
110 participants

Conditions and interventions

Interventions

  • brentuximab vedotin Drug

Drug

Eligibility (public fields only)

Age range
6 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2009
Primary completion
Feb 28, 2013
Completion
Feb 28, 2013
Last update posted
Feb 1, 2017

2009 – 2013

United States locations

U.S. sites
16
U.S. states
13
U.S. cities
15
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35294-3300
City of Hope National Medical Center Duarte California 91010
Stanford Cancer Center Stanford California 94305
Colorado Blood Cancer Institute Denver Colorado 80218
University of Miami Miller School of Medicine / Sylvester Comprehensive Cancer Center Miami Florida 33136
Loyola University Medical Center - Cardinal Bernadin Cancer Center Maywood Illinois 60153
St. Francis Medical Group Oncology & Hematology Specialists Indianapolis Indiana 46237
Karmanos Cancer Institute / Wayne State University Detroit Michigan 48201
Washington University School of Medicine St Louis Missouri 63110
The John Theurer Cancer Center, Hackensack University Medical Center Hackensack New Jersey 07601
NYU Clinical Cancer Center New York New York 10016
Columbia University Medical Center New York New York 10019
Nationwide Children's Hospital Columbus Ohio 43205
Charles A. Sammons Cancer Center Dallas Texas 75246
MD Anderson Cancer Center /The University of Texas Houston Texas 77030
Seattle Cancer Care Alliance / University of Washington Medical Center Seattle Washington 98109-1023

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00947856, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 1, 2017 · Synced May 15, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00947856 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →